drugset / Trial / NCT01407497

Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine

NCT01407497

RandomizedParallel-groupQuadruple-blindPrevention

Summary

While antiretroviral drugs have shown great promise in reducing HIV replication and thus in reducing HIV/AIDS associated morbi-mortality and HIV transmission, the cost is substantial and side effects are a potentially limiting factor. Development of an effective safe-affordable vaccine is likely to be the best way to stop further virus spread. The study aims to determine safety and immunogenicity of the DNA-vaccine at a dose of 600µg and 1200µg delivered id in combination with MVA-CMDR boost im.

Timeline

Start
2011-08
Primary completion
2013-03
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator DNA HIVIS Vaccine 600 ug Intravenous
Comparator DNA HIVIS Vaccine 1200 ug Intravenous
Comparator MVA-CMDR Vaccine 108 unknown Intramuscular